The University of Texas MD Anderson Cancer Center | Strategic Alliance Partners
The University of Texas MD Anderson Cancer Center in Houston ranks as one of the world's most respected centers focused on cancer patient care, research, education and prevention. The institution’s sole mission is to end cancer for patients and their families around the world, and, in 1971, it became one of the nation’s first National Cancer Institute (NCI)-designated comprehensive cancer centers. MD Anderson is No. 1 for cancer in U.S. News & World Report’s “Best Hospitals” rankings and has been named one of the nation’s top two hospitals for cancer since the rankings began in 1990.
Through integrated and comprehensive programs, MD Anderson advances transformative discovery, prevention, translational and clinical research. We aim to provide a deeper understanding of all cancer types, including rare cancers not often studied or treated elsewhere, to ultimately lead to meaningful benefits for patients and society. In fiscal year 2024, MD Anderson invested $1.3 billion in research efforts. MD Anderson also is home to world’s largest oncology clinical trials program, with more than 1,500 ongoing trials in FY24, and 27 drugs tested at MD Anderson received FDA approval in FY24.
Through partnership with our patients, our scientists and clinicians seamlessly collaborate to develop breakthroughs that transform the field. Discoveries from our labs are swiftly translated into new therapies in the clinic, and insights from the clinic inform our laboratory work in real time. At every step, a rapidly growing team of data scientists provide insights, processes and tools that better inform and accelerate studies. Our culture of collaboration provides early-career researchers accessible mentorship and hands-on training from some of the most brilliant minds in the world across the spectrum of cancer research and care.
Latest from The University of Texas MD Anderson Cancer Center
Two MD Anderson Researchers Elected AAAS Fellows
April 02, 2025
Article
Lung cancer clinician and prevention expert recognized for their achievements in advancing cancer care and research.
Ivonescimab Shows Significant PFS Improvement Over Pembrolizumab in PD-L1+ NSCLC
March 31, 2025
Article
Xiuning Le, MD, PhD, discusses data from the HARMONi-2 trial of ivonescimab vs pembrolizumab in PD-L1–positive NSCLC.
Ivonescimab Improves PFS vs Pembrolizumab in Advanced PD-L1+ NSCLC: With Xiuning Le, MD, PhD
March 24, 2025
Podcast
Xiuning Le, MD, PhD, discusses the HARMONi-2 trial of ivonescimab in patients with advanced PD-L1–positive non–small cell lung cancer.
Ponatinib Monotherapy Maintains MRD Negativity Following TKI/Chemotherapy Treatment in Ph+ ALL: With Ibrahim T. Aldoss, MD; and Elias Jabbour, MD
March 20, 2025
Podcast
Drs Aldoss and Jabbour discuss an analysis of PhALLCON that support the use of ponatinib monotherapy after TKI/chemotherapy treatment in Ph-positive ALL.
IL-Agonist NKTR-255 Shows Ability to Enhance Responses to CAR T-Cell Therapy in R/R LBCL
March 20, 2025
Article
Sairah Ahmed, MD, discusses findings from a phase 2 trial of NKTR-255 after CD19-directed CAR T-cell therapy in relapsed/refractory LBCL.
Dr Westin on PFS Benefit With DUO-E Regimen Across Histologic and Molecular pMMR Endometrial Cancer Subgroups
March 17, 2025
Video
Shannon Westin, MD, MPH, FACOG, discusses the efficacy of durvalumab plus chemotherapy and olaparib in pMMR recurrent endometrial cancer.
Dr Ahmed on Challenges Treating Patients With R/R LBCL Following Exposure to CAR T-Cell Therapy
March 05, 2025
Video
Sairah Ahmed, MD, discusses treatment challenges for patients with relapsed/refractory large B-cell lymphoma following CAR T-cell therapy.
Toxicity, Sequencing Considerations Are Key for Frontline Chemotherapy Selection in Metastatic Pancreatic Cancer
March 04, 2025
Article
Brandon G. Smaglo, MD, FACP, discusses upfront treatment considerations for patients with metastatic pancreatic cancer.
Ivosidenib/CPX-351 Shows Early Activity and Is Safe in IDH1-Mutated R/R AML, High-Risk MDS
March 04, 2025
Article
Treatment with ivosidenib plus CPX-351 showed early efficacy in patients with relapsed/refractory AML or high-risk MDS harboring an IDH1 mutation.
Dr Smaglo on Selecting Between Frontline Chemotherapy Regimens for Pancreatic Cancer
February 28, 2025
Video
Brandon G. Smaglo, MD, FACP, discusses considerations for choosing between frontline chemotherapy-based regimens for patients with pancreatic cancer.
Cardio-Oncology Investigations Begin to Uncover More Links Between CVD and Breast Cancer
February 26, 2025
Article
For American Heart Month, cardiologist Amy M. Ahnert, MD, and oncologist Kevin T. Nead, MD, MPhil, unpacked the link between CVD and breast cancer.
MD Anderson Receives Nearly $23 Million in CPRIT Funding for Cancer Research, Faculty Recruitment
February 25, 2025
Article
MD Anderson was awarded nearly $23 million from the CPRIT for cancer research and faculty recruitment.
Pan-Tumor Approvals Stress the Need for Harmonized Testing and Reporting Strategies
February 21, 2025
Article
Funda Meric-Bernstam, MD, highlights considerations with pan-tumor approvals and where testing and reporting should be improved for clarity/ease.
UT MD Anderson and Texas Children’s Hospital Announce Joint Venture to End Childhood Cancer
February 20, 2025
Article
The University of Texas MD Anderson Cancer Center and Texas Children’s Hospital have announced a collaboration dedicated to pediatric cancer care.
Experts Break Down Practice-Informing Presentations From the 2025 Genitourinary Cancers Symposium
February 19, 2025
Article
Experts across the field of GU oncology share important insights and spotlight key research presented at the 2025 GU Cancers Symposium.
Biomarker-Driven Research Accelerates Drug Discovery and Precision Medicine Approaches in Sarcoma
February 18, 2025
Article
Neeta Somaiah, MD, highlights the evolving sarcoma treatment paradigm within the past 5 years, including the FDA approval of afamitresgene autoleucel.
Dato-DXd Prolongs Responses in Pretreated Advanced/Metastatic Urothelial Cancer
February 15, 2025
Article
Dato-DXd generated durable responses and produced no new safety signals in patients with heavily pretreated, locally advanced/metastatic urothelial cancer.
Dr Meric-Bernstam on the Efficacy and Safety of Dato-DXd in Metastatic Urothelial Cancer
February 15, 2025
Video
Dr Somaiah on Ongoing Research With Novel Agents in Sarcomas
February 12, 2025
Video
Neeta Somaiah, MD, discusses ongoing research with novel agents that have emerged and those that could soon emerge in the sarcoma treatment paradigm.
Ponatinib-Based Regimens Strengthen the Ph+ ALL Treatment Paradigm: With Mark B. Geyer, MD, and Elias Jabbour, MD
February 10, 2025
Podcast
Drs Geyer and Jabbour discuss ponatinib in Ph+ ALL, data with this agent plus blinatumomab, and how the safety profile of ponatinib affects its use.